Abstract：Objective To study the demographic features of children with allergic diseases receiving standardized sublingual immunotherapy (SLIT) and the influencing factors for the compliance with SLIT. Methods A retrospective analysis was performed on the demographic features and follow-up data of 1 789 children with allergic diseases who received SLIT in Children's Hospital of Jiangxi Province from January 1, 2018 to December 31, 2020. The compliance with SLIT and its influencing factors were analyzed. Results A total of 1 789 children received SLIT, among whom there were 1 271 boys (71.05%) and 518 girls (28.95%), with an age range of 4-14 years. Among these children, 777 (43.43%) had complete compliance with SLIT and 1 012 (56.57%) withdrew from the treatment within one year. Among the 1 012 children, 354 (34.98%) withdrew from the treatment due to self-conscious inconvenient use, 346 (34.19%) withdrew due to unsatisfactory treatment outcome, 253 (25.00%) stopped the treatment due to the improvement in symptoms, and 59 (5.83%) terminated the treatment due to adverse reactions. Withdrawal was mainly observed within 1-4 months after treatment (74.31%, 752/1 012). Girls tended to have a lower compliance rate than boys, and the children with a single disease had a lower compliance rate than those with multiple diseases (P<0.05). The multivariate analysis showed that compared with boys, girls had an increased risk of withdrawal (OR=0.811, 95%CI: 0.658-0.998, P<0.05), and compared with the children with multiple diseases, the children with a single disease were more likely to withdraw from the treatment (OR=1.313, 95%CI: 1.005-1.715, P<0.05). Conclusions Children with allergic diseases tend to have poor compliance with SLIT, which is associated with sex and the number of diseases, and the main reasons for withdrawal are self-conscious inconvenient use and unsatisfactory treatment outcome.
HUANG Rong-Rong,ZHU Xiao-Hua,WANG Jin-Ling. Demographic features and compliance of children with allergic diseases receiving sublingual immunotherapy[J]. CJCP, 2022, 24(12): 1371-1375.
Kim JA, Lee YM, Yi KI, et al. Comparative analysis of sublingual immunotherapy medicines for adherence and clinical outcomes[J]. Eur Arch Otorhinolaryngol, 2020, 277(1): 135-140. PMID: 31542829. DOI: 10.1007/s00405-019-05656-6.
Vogelberg C, Brüggenjürgen B, Richter H, et al. Real-world adherence and evidence of subcutaneous and sublingual immunotherapy in grass and tree pollen-induced allergic rhinitis and asthma[J]. Patient Prefer Adherence, 2020, 14: 817-827. PMID: 32494127. PMCID: PMC7231771. DOI: 10.2147/PPA.S242957.
Chen WB, Shen XF, Li Q, et al. Efficacy of a 3-year course of sublingual immunotherapy for mite-induced allergic rhinitis with a 3-year follow-up[J]. Immunotherapy, 2020, 12(12): 891-901. PMID: 32693660. DOI: 10.2217/imt-2020-0006.
Kim JY, Rhee CS, Mun SJ, et al. Early response of specific IgE can predict satisfaction with sublingual immunotherapy[J]. Laryngoscope, 2021, 131(3): 467-472. PMID: 32562508. DOI: 10.1002/lary.28762.
Wijga A, Tabak C, Postma DS, et al. Sex differences in asthma during the first 8 years of life: the prevention and incidence of asthma and mite allergy (PIAMA) birth cohort study[J]. J Allergy Clin Immunol, 2011, 127(1): 275-277. PMID: 21094994. DOI: 10.1016/j.jaci.2010.09.022.
